Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Videos

The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]

Reasons to Attend the 2023 Advanced Therapeutics in Movement & Related Disorders Congress: Fernando Pagan, MD; Yasar Torres-Yaghi, MD

Articles

The chief medical officer of Harmony Biosciences provided perspective on a proof-of-concept study assessing pitolisant’s (Wakix) clinical benefit in reducing excessive daytime sleepiness individuals with Prader-Willi syndrome. 

NeuroVoices: Kumar Budur, MD, on Pitolisant’s Impact in Excessive Daytime Sleepiness, Prader-Willi Syndrome

Carolyn H. Goldschmidt, DO, a neurologist at NorthShore University Health System in Chicago, talked about a retrospective study analyzing disease-modifying therapies in multiple sclerosis patients at CMSC 2023.

Bridging the Gap, De-Escalation of MS Disease Modifying Therapies: Carolyn H Goldschmidt, DO

The companies have noted that the decision was not made because of safety or efficacy data, but to refocus efforts on the ongoing phase 2b LUMA trial of BIIB122.

Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease

Vice Chairman, Department of Neurology; Director, Movement Disorders Program; 

Medical Director, Georgetown University Hospital National Parkinsonism Foundation Center of Excellence; 

Medical Director, Translational Neurotherapeutics Program; 

Associate Professor, Department of Neurology, Georgetown University

, has been with the team since September 2022. Follow her on Twitter 

Neurologist, Oregon Health State University

The professor of neurology at Oregon Health & Science University talked about a study on a modified low-fat diet intervention and its effects on fatigue in patients with multiple sclerosis over a 16-week period at CMSC 2023. [WATCH TIME: 8 minutes] 

Investigating the Impact of a Low-Fat Diet on Quality of Life and Symptom Management in MS: Vijayshree Yadav, MD, MCR, FANA, FAAN

Patients with multiple sclerosis who presented with high-stress maintained their stress management practice through later protocol sessions, according to a study a recent study.

Stress Management Protocol Reduces Depression and Anxiety in Patients With MS: Amy Sullivan, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

Ataxia

CMSC 2023

NMOSD

Narcolepsy

Parkinson Disease

SLEEP 2023

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

Authors

The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals provided insight into how fremanezumab has helped to improve these facets of the condition.

Joshua Cohen, MD: Fremanezumab's Impact on Quality of Life and Comorbidities

The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals, the therapy’s developer, discussed its performance in patients with medication overuse headache.

Joshua Cohen, MD: Fremanezumab for Medication Overuse Headache